BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
BIOCRYST PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Acquired in-process research and development → operating reconciliation: $697,761,000.00Stock-based compensation expense → operating reconciliation: $30,719,000.00Non-cash interest expense on royalty financing obligations → operating reconciliation: $26,330,000.00Increase in deferred revenue → operating reconciliation: $10,793,000.00Decrease in prepaid expenses and other assets → operating reconciliation: $7,964,000.00Mark-to-market adjustment on share-based liability → operating reconciliation: $3,331,000.00Depreciation → operating reconciliation: $974,000.00Amortization of assembled workforce → operating reconciliation: $600,000.00Inventory obsolescence → operating reconciliation: $583,000.00Amortization of debt issuance costs on term loans → operating reconciliation: $352,000.00operating reconciliation → Net cash from operating activities: $42,551,000.00operating reconciliation → Net (loss) income: $643,417,000.00operating reconciliation → Decrease in accounts payable and accrued expenses: $55,330,000.00operating reconciliation → Decrease in royalty financing obligations: $26,788,000.00operating reconciliation → (Increase) decrease in inventory: $9,196,000.00operating reconciliation → Increase in trade receivables: $1,959,000.00operating reconciliation → Amortization of discount on investments, net: $166,000.00Proceeds from term loan → financing reconciliation: $400,000,000.00Net proceeds from common stock issued under stock-based compensation plans → financing reconciliation: $25,682,000.00Common stock issued to directors in lieu of cash retainer → financing reconciliation: $77,000.00financing reconciliation → Net cash from financing activities: $401,399,000.00financing reconciliation → Principal payments on royalty financing obligations: $13,823,000.00financing reconciliation → Payment of debt issuance costs on term loan: $4,952,000.00financing reconciliation → Withholding taxes paid on stock-based awards: $4,879,000.00financing reconciliation → Principal payments on finance lease liabilities: $706,000.00Net cash used in investing activities → investing reconciliation: $378,796,000.00Sales and maturities of investments → investing reconciliation: $246,931,000.00investing reconciliation → Acquisition of Astria Therapeutics, Inc., net of cash acquired: $489,480,000.00investing reconciliation → Purchases of investments: $135,635,000.00investing reconciliation → Acquisitions of property and equipment: $612,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $91,337,000.00Net cash from operating activities → Cash sources and uses: $42,551,000.00Net cash from financing activities → Cash sources and uses: $401,399,000.00Cash sources and uses → Other changes in cash (calculated): $107,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $156,384,000.00Cash sources and uses → Net cash used in investing activities: $378,796,000.00Net (loss) income: -$643,417,000.00Net (loss) income−$643.42 MDepreciation: $974,000.00Depreciation expense+$974.00 KAcquired in-process research and development: $697,761,000.00Acquired in-process R&D+$697.76 MAmortization of assembled workforce: $600,000.00Intangible amortization+$600.00 KInventory obsolescence: $583,000.00Inventory write-downs+$583.00 KStock-based compensation expense: $30,719,000.00Stock-based compensation+$30.72 MMark-to-market adjustment on share-based liability: $3,331,000.00Share-based liability FV+$3.33 MPayment of Pharmakon paid-in-kind interest: $0.00Non-cash interest expense on royalty financing obligations: $26,330,000.00Non-cash royalty interest+$26.33 MAmortization of debt issuance costs on term loans: $352,000.00Term loan issuance cost amort.+$352.00 KAmortization of discount on investments, net: -$166,000.00Investment discount amort., net−$166.00 KLoss on extinguishment of debt: $0.00Increase in trade receivables: -$1,959,000.00Receivables, net−$1.96 M(Increase) decrease in inventory: -$9,196,000.00Inventories−$9.20 MDecrease in prepaid expenses and other assets: $7,964,000.00Prepaid & other assets+$7.96 MDecrease in royalty financing obligations: -$26,788,000.00Royalty financing obligations−$26.79 MDecrease in accounts payable and accrued expenses: -$55,330,000.00Accounts payable−$55.33 MIncrease in deferred revenue: $10,793,000.00Deferred revenue+$10.79 MNet cash from operating activities: $42,551,000.00Operating cash+$42.55 Moperating reconciliation: $779,407,000.00Net proceeds from common stock issued under stock-based compensation plans: $25,682,000.00Employee stock plans & options+$25.68 MWithholding taxes paid on stock-based awards: -$4,879,000.00Stock-award tax withholding−$4.88 MCommon stock issued to directors in lieu of cash retainer: $77,000.00Director retainer stock issued+$77.00 KProceeds from term loan: $400,000,000.00Long-term debt issued+$400.00 MRepayment of Pharmakon term loan principal: $0.00Prepayment premium and fees on Pharmakon term loan: $0.00Payment of debt issuance costs on term loan: -$4,952,000.00Debt issuance costs−$4.95 MPrincipal payments on royalty financing obligations: -$13,823,000.00Royalty financing repaid−$13.82 MPrincipal payments on finance lease liabilities: -$706,000.00Finance lease payments−$706.00 KNet cash from financing activities: $401,399,000.00Financing cash+$401.40 Mfinancing reconciliation: $425,759,000.00Acquisitions of property and equipment: -$612,000.00Capital expenditures−$612.00 KPurchases of investments: -$135,635,000.00AFS securities purchases−$135.64 MSales and maturities of investments: $246,931,000.00AFS securities proceeds+$246.93 MAcquisition of Astria Therapeutics, Inc., net of cash acquired: -$489,480,000.00Acquisitions, net of cash−$489.48 MNet cash used in investing activities: -$378,796,000.00. Cash required to fund net payments.Investing cash−$378.80 Minvesting reconciliation: $625,727,000.00Cash sources and uses: $535,287,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $91,337,000.00Beginning cash$91.34 MEnding cash: Cash, cash equivalents, and restricted cash: $156,384,000.00Ending cash$156.38 MOther changes in cash (calculated): -$107,000.00Other changes in cash(calculated)−$107.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsNet loss −$643.42M + net operating adjustments $685.97M = operating cash +$42.55MFree cash flow$41.94 MOperating cash − cash spent on productive assetsCash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$65.05 MEnding cash − beginning cash
Chart details

BIOCRYST PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
91,337,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
42,551,000 US dollars. Net cash provided.
Net (loss) income
negative 643,417,000 US dollars
Depreciation
974,000 US dollars
Acquired in-process research and development
697,761,000 US dollars
Amortization of assembled workforce
600,000 US dollars
Inventory obsolescence
583,000 US dollars
Stock-based compensation expense
30,719,000 US dollars
Mark-to-market adjustment on share-based liability
3,331,000 US dollars
Payment of Pharmakon paid-in-kind interest
0 US dollars
Non-cash interest expense on royalty financing obligations
26,330,000 US dollars
Amortization of debt issuance costs on term loans
352,000 US dollars
Amortization of discount on investments, net
negative 166,000 US dollars
Loss on extinguishment of debt
0 US dollars
Increase in trade receivables
negative 1,959,000 US dollars
(Increase) decrease in inventory
negative 9,196,000 US dollars
Decrease in prepaid expenses and other assets
7,964,000 US dollars
Decrease in royalty financing obligations
negative 26,788,000 US dollars
Decrease in accounts payable and accrued expenses
negative 55,330,000 US dollars
Increase in deferred revenue
10,793,000 US dollars
Investing activities
negative 378,796,000 US dollars. Net cash used.
Acquisitions of property and equipment
negative 612,000 US dollars
Purchases of investments
negative 135,635,000 US dollars
Sales and maturities of investments
246,931,000 US dollars
Acquisition of Astria Therapeutics, Inc., net of cash acquired
negative 489,480,000 US dollars
Financing activities
401,399,000 US dollars. Net cash provided.
Net proceeds from common stock issued under stock-based compensation plans
25,682,000 US dollars
Withholding taxes paid on stock-based awards
negative 4,879,000 US dollars
Common stock issued to directors in lieu of cash retainer
77,000 US dollars
Proceeds from term loan
400,000,000 US dollars
Repayment of Pharmakon term loan principal
0 US dollars
Prepayment premium and fees on Pharmakon term loan
0 US dollars
Payment of debt issuance costs on term loan
negative 4,952,000 US dollars
Principal payments on royalty financing obligations
negative 13,823,000 US dollars
Principal payments on finance lease liabilities
negative 706,000 US dollars
Operating adjustment reconciliation
779,407,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
425,759,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
625,727,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Other changes in cash (calculated)
negative 107,000 US dollars. Out of cash; drawn as the small gray flow above ending cash.
Ending cash on Jun 30, 2026
156,384,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
535,287,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
65,047,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
42,551,000 US dollars. Operating cash flow used in the free cash flow calculation.
cash spent on productive assets
612,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
41,939,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$643.42M + net operating adjustments $685.97M = operating cash +$42.55M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash spent on productive assets equals free cash flow: 42,551,000 US dollars minus 612,000 US dollars equals 41,939,000 US dollars.
BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!